BridgeBio Pharma Inc
BBIO47.615USD
+0.245+0.52%
交易中 （美東）報價延遲15分鐘
9.04B總市值
虧損本益比TTM
關於 BridgeBio Pharma Inc 公司
BridgeBio Pharma, Inc. 是一家商業階段的生物製藥公司。該公司專注於發現、創造、測試和提供變革性藥物，以治療患有具有明確遺傳驅動因素的遺傳疾病和癌症的患者。該公司的開發項目範圍從早期科學到高級臨牀試驗，包括用於治療澱粉樣變性 TTR (ATTR) 的下一代小分子近乎完全的轉甲狀腺素蛋白 (TTR) 穩定劑 Acoramidis (AG10)；低劑量 infigratinib，一種口服 FGFR1-3 選擇性酪氨酸激酶抑制劑 (TKI)，作爲軟骨發育不全兒童的治療選擇； Encaleret 是一種鈣敏感受體（CaSR）小分子拮抗劑，用於治療 1 型常染色體顯性低鈣血癥（ADH1）；BBP-418 是一種在研的口服小分子底物補充療法，該公司正在開發用於治療 LGMD2I（也稱爲 LGMDR9）。
公司簡介
公司代碼BBIO
公司名稱BridgeBio Pharma Inc
上市日期Jun 27, 2019
CEODr. Neil Kumar, Ph.D.
員工數量725
證券類型Ordinary Share
年結日Jun 27
公司地址3160 Porter Dr.
城市PALO ALTO
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編94304
電話16503919740
網址https://bridgebio.com/
公司代碼BBIO
上市日期Jun 27, 2019
CEODr. Neil Kumar, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Neil Kumar, Ph.D.
Dr. Neil Kumar, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
6.16M
+0.09%
Dr. Charles J. Homcy, M.D.
Dr. Charles J. Homcy, M.D.
Lead Director, Chairman of Pharmaceuticals
Lead Director, Chairman of Pharmaceuticals
1.22M
-1.09%
Mr. Ali J. Satvat
Mr. Ali J. Satvat
Independent Director
Independent Director
165.99K
+4.13%
Mr. James C. (Jim) Momtazee
Mr. James C. (Jim) Momtazee
Independent Director
Independent Director
95.08K
+7.45%
Dr. Thomas Trimarchi, Ph.D.
Dr. Thomas Trimarchi, Ph.D.
President, Chief Financial Officer
President, Chief Financial Officer
57.85K
-26.92%
Mr. Fred Hassan
Mr. Fred Hassan
Lead Independent Director
Lead Independent Director
25.89K
+34.14%
Mr. Ronald J. Daniels, J.D.
Mr. Ronald J. Daniels, J.D.
Independent Director
Independent Director
16.99K
+63.34%
Dr. Randal W. (Randy) Scott, Ph.D.
Dr. Randal W. (Randy) Scott, Ph.D.
Independent Director
Independent Director
15.59K
+73.21%
Ms. Jennifer E. Cook
Ms. Jennifer E. Cook
Independent Director
Independent Director
13.74K
+92.13%
Dr. Eric Aguiar, M.D.
Dr. Eric Aguiar, M.D.
Independent Director
Independent Director
6.59K
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Neil Kumar, Ph.D.
Dr. Neil Kumar, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
6.16M
+0.09%
Dr. Charles J. Homcy, M.D.
Dr. Charles J. Homcy, M.D.
Lead Director, Chairman of Pharmaceuticals
Lead Director, Chairman of Pharmaceuticals
1.22M
-1.09%
Mr. Ali J. Satvat
Mr. Ali J. Satvat
Independent Director
Independent Director
165.99K
+4.13%
Mr. James C. (Jim) Momtazee
Mr. James C. (Jim) Momtazee
Independent Director
Independent Director
95.08K
+7.45%
Dr. Thomas Trimarchi, Ph.D.
Dr. Thomas Trimarchi, Ph.D.
President, Chief Financial Officer
President, Chief Financial Officer
57.85K
-26.92%
Mr. Fred Hassan
Mr. Fred Hassan
Lead Independent Director
Lead Independent Director
25.89K
+34.14%
收入明細
單位: USD更新時間: 7月6日 週日
單位: USD更新時間: 7月6日 週日
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
暫無數據
地區USD
名稱
營收
佔比
Europe Middle East and Africa (EMEA)
77.09M
66.10%
United States
36.86M
31.60%
Asia Pacific (APAC)
2.68M
2.30%
業務
地區
暫無數據
股東統計
更新時間: 5月16日 週五
更新時間: 5月16日 週五
持股股東
股東類型
持股股東
持股股東
佔比
Viking Global Investors LP
9.80%
The Vanguard Group, Inc.
8.68%
Kohlberg Kravis Roberts & Co. L.P.
6.98%
BlackRock Institutional Trust Company, N.A.
5.89%
Janus Henderson Investors
3.78%
Other
64.87%
持股股東
持股股東
佔比
Viking Global Investors LP
9.80%
The Vanguard Group, Inc.
8.68%
Kohlberg Kravis Roberts & Co. L.P.
6.98%
BlackRock Institutional Trust Company, N.A.
5.89%
Janus Henderson Investors
3.78%
Other
64.87%
股東類型
持股股東
佔比
Investment Advisor
32.61%
Investment Advisor/Hedge Fund
31.42%
Hedge Fund
15.71%
Private Equity
8.99%
Individual Investor
4.95%
Research Firm
3.23%
Venture Capital
1.89%
Sovereign Wealth Fund
0.56%
Bank and Trust
0.49%
Other
0.16%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
620
190.27M
100.20%
-5.13M
2025Q1
628
200.01M
105.33%
-2.20M
2024Q4
586
190.11M
100.07%
-10.58M
2024Q3
566
185.43M
98.60%
-19.02M
2024Q2
541
188.12M
100.51%
-8.17M
2024Q1
529
185.29M
101.24%
-2.60M
2023Q4
525
179.04M
102.35%
-7.24M
2023Q3
519
174.99M
102.35%
-1.47M
2023Q2
503
162.75M
101.40%
-17.06M
2023Q1
513
164.96M
102.84%
-5.53M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Viking Global Investors LP
18.56M
9.77%
-3.50M
-15.87%
Jun 27, 2025
The Vanguard Group, Inc.
14.87M
7.83%
-177.77K
-1.18%
Mar 31, 2025
Kohlberg Kravis Roberts & Co. L.P.
13.26M
6.98%
-6.00M
-31.15%
May 12, 2025
BlackRock Institutional Trust Company, N.A.
11.18M
5.89%
-318.26K
-2.77%
Mar 31, 2025
Janus Henderson Investors
7.17M
3.78%
+2.26M
+46.13%
Mar 31, 2025
Kumar (Neil)
6.16M
3.25%
+5.69K
+0.09%
May 19, 2025
Aisling Capital Management LP
6.07M
3.2%
--
--
Mar 31, 2025
State Street Global Advisors (US)
5.75M
3.03%
-433.01K
-7.00%
Mar 31, 2025
Farallon Capital Management, L.L.C.
5.73M
3.02%
+1.54M
+36.62%
Mar 31, 2025
Capital Research Global Investors
4.67M
2.46%
+1.14M
+32.34%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Tema Oncology ETF
4.11%
Tema Heart & Health ETF
3.19%
Franklin Genomic Advancements ETF
2.39%
SPDR S&P Biotech ETF
2.15%
Virtus LifeSci Biotech Products ETF
2.1%
Direxion Daily S&P Biotech Bull 3X Shares
1.23%
Invesco Nasdaq Biotechnology ETF
0.91%
ProShares Ultra Nasdaq Biotechnology
0.91%
First Trust Mid Cap Growth AlphaDEX Fund
0.83%
iShares Health Innovation Active ETF
0.8%
查看更多
Tema Oncology ETF
佔比4.11%
Tema Heart & Health ETF
佔比3.19%
Franklin Genomic Advancements ETF
佔比2.39%
SPDR S&P Biotech ETF
佔比2.15%
Virtus LifeSci Biotech Products ETF
佔比2.1%
Direxion Daily S&P Biotech Bull 3X Shares
佔比1.23%
Invesco Nasdaq Biotechnology ETF
佔比0.91%
ProShares Ultra Nasdaq Biotechnology
佔比0.91%
First Trust Mid Cap Growth AlphaDEX Fund
佔比0.83%
iShares Health Innovation Active ETF
佔比0.8%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
